Less immunogenic binding molecules

A technology that combines molecules and molecules, applied in the direction of immunoglobulins, hybrid immunoglobulins, and anti-animal/human immunoglobulins, and can solve problems such as reducing specific activity

Inactive Publication Date: 2007-04-18
MICROMET AG
View PDF26 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] However, it was observed that humanized antibody constructs from OKT3 in the form of bispecific binding mo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Less immunogenic binding molecules
  • Less immunogenic binding molecules
  • Less immunogenic binding molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] Generation of humanized antibodies specific to CD3 antigen

[0155] Refer to Kabat, EA, et al., "Sequences of Proteins of Immunological Interest", 5th Edition, Volume 3, Bethesda, MD: National Institutes of Health. National Center for Biotechnology Information, 1991; 2597. NIH Publication No. 91-3242 CD3 to determine CD3 specificity Location of the CDRs of the antibody OKT3.

[0156] The human framework regions chosen to accept the grafted CDRs were the KOL for the heavy chain and the REI for the light chain, respectively. The structures of these proteins have been solved by crystallography (REI: Palm (1975) Hoppe Seylers Z Physiol Chem 356, 167-191, KOL: Schmidt (1983) Hoppe Seylers Z Physiol Chem 364, 713-747.).

[0157] According to Adair 1994 Hum. Antibod. Hybridomas, 5:41-48, a number of additional murine residues were introduced into the human variable region framework. These altered residues are important for maintaining original antigen specificity. Additiona...

Embodiment 2

[0160] Construction of bispecific single chain antibodies with humanized anti-CD3 moiety

Embodiment 21

[0162] Construction of a bispecific single chain anti-CD19×anti-CD3 antibody with a humanized anti-CD3 portion

[0163] The DNA encoding the scFv of the generated humanized antibody was obtained by gene synthesis and fused with the CD19-specific scFv gene to obtain a bispecific single chain antibody ( FIG. 1B , SEQ ID NO: 19, 20). The bispecific single chain antibody was subcloned into the mammalian expression vector pEF-DHFR with restriction enzymes EcoRI and SalI.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains whereby one of said at least two domains specifically binds to/interacts with the human CD3 complex and said domain comprises an amino acid sequence of an antibody derived light chain, wherein said amino acid sequence is a particularly identified amino acid sequence comprising specific amino acid substitutions, and a second domain is or contains at least one further antigen-interaction-site and/or at least one further effector domain. The invention further provides nucleic acid molecules encoding the bispecific binding molecules of the invention, vectors comprising said nucleic acid molecules and host cells transformed or transfected with said vectors. Moreover, the invention concerns a method for the production of bispecific binding molecules of the invention and compositions comprising the bispecific binding molecules of the invention, the nucleic acid molecules of the invention or the host cells of the invention.

Description

technical field [0001] The present invention provides a bispecific binding molecule, wherein said molecule comprises or consists of at least two domains, wherein one of said at least two domains specifically binds / interacts with a human CD3 complex and said domain comprising a light chain amino acid sequence from an antibody, wherein said amino acid sequence is a specifically identified amino acid sequence containing specific amino acid substitutions, and the other domain is or contains at least one other antigen interaction site and / or at least one other effector domain. The present invention also provides nucleic acid molecules encoding the bispecific binding molecules of the present invention, vectors containing said nucleic acid molecules and host cells transformed with said vectors. In addition, the invention relates to methods of producing bispecific binding molecules of the invention and compositions comprising bispecific binding molecules of the invention, nucleic aci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/28C07K16/30C07K16/46A61K39/395A61P31/00A61P33/00A61P35/00A61P37/00
CPCC07K2317/622C07K16/2809C07K2317/31C07K2317/34C07K16/30C07K16/2803A61P29/00A61P31/00A61P31/04A61P31/12A61P33/00A61P35/00A61P37/00A61P37/06A61P37/08C07K16/18C07K16/28
Inventor P·库弗U·伦凯里-许茨R·卢特比泽B·科赫莱森
Owner MICROMET AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap